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Abstract
Busulfan, a chemotherapy drug, causes a variety of adverse effects, such as damage to the reproductive system of male
cancer patients. The aim of this study was to investigate the protective effect of intra-peritoneal (IP) injection of
exogenous melatonin and atorvastatin alone and in combination on busulfan-induced spermatogenesis injuries and
oxidative stress activity in a rat model. A total of 36 male Wistar rats (220–250 g) (n = 6) were randomly divided into
six different groups, including atorvastatin, melatonine, sham (received DMSO or busulfan solvent), busulfan, atorva-
statin + melatonine, and control groups. Busulfan was diluted in DMSO and intra-peritoneally (IP) administrated in two
doses of 25 and 10 mg/kg with a 14-day interval in all groups except the control and sham groups. Administration of
atorvastatin and melatonin started 1 day after injection of busulfan. After 28 days, the animals were euthanized and the
semen was collected from epididymis and the testicular tissues were removed for sperm parameter assessment and
biochemical analysis, including super oxide dismutase (SOD), SOD/total protein (TP), catalase, catalase/TP, and
MDA. The highest and lowest values of sperm parameters belonged to the control and busulfan groups, respectively,
followed by sham, atorvastatin + melatonine, melatonin, and atorvastatin groups as well as antioxidant enzyme activity.
However, MDA activity in the busulfan group was significantly increased compared to that in the other groups. In
conclusion, the results of the present study indicated that co-administration of melatonin and atorvastatin and mono-
therapy can attenuate busulfan-induced spermatogenesis injuries in rats via reducing oxidative stress.
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Introduction
Preservation of fertility is an important priority in cancer treat-
ment and bone marrow transplantation (BMT) (Zhang et al.
2019). Busulfan is an effective cancer therapy agent which is
widely administrated for cancer treatment, such as lympho-
mas, myelo-proliferative disorders, chronic myelogenous leu-
kemia and other types of leukemia, and before BMT
(Goldman 2010; Talpaz et al. 2013). However, busulfan is
known to cause various adverse effects, such as male repro-
ductive toxicity (Nasimi et al. 2018) including increased ab-
normal sperm parameters, decreased testis weight (Hosseini
et al. 2014; Suriapraba et al. 2012), oligo-azoospermia,
destroyed testicular germ cells, and temporary or permanent
infertility (Anjamrooz et al. 2007). Since busulfan is a cell
cycle nonspecific alkylating antineoplastic agent with oxida-
tive properties, it is believed that antioxidant therapy can re-
duce its adverse effects (GanjalikhanHakemi et al. 2013). One
* Sadegh Shirian
shirian85@gmail.com
1 Department of Veterinary Basic Science, Science and Research
Branch, Islamic Azad University, Tehran, Iran
2 Department of Pathology, Faculty of Veterinary Medicine,
Shahrekord University, Shahrekord, Iran
3 Biotechnology Research Inistitute, Shahrekord University,
Shahrekord, Iran
4 Shiraz Molecular Pathology Research Center, Dr Daneshbod Lab,
Shiraz, Iran
5 Department of Clinical Science, Faculty of Veterinary Medicine,
Shahrekord University, Shahrekord, Iran
6 Research Institute of Animal Embryo Technology, Shahrekord
University, Shahrekord, Iran
7 Department of Pharmacology, School of Medicine, Qazvin
University of Medical Sciences, Qazvin, Iran
https://doi.org/10.1007/s00580-019-03040-8
Comparative Clinical Pathology (2020) 29:161–166
/Published online: 10 August 2019
